Pharmacogenetic Approach to Toxicity in Breast Cancer Patients Treated with Taxanes

被引：11

作者：

Angelini, Silvia ^{[1
,2
]}

Botticelli, Andrea ^{[1
]}

Onesti, Concetta Elisa ^{[1
,2
]}

Giusti, Raffaele ^{[2
]}

Sini, Valentina ^{[1
,3
]}

Durante, Valeria ^{[1
,2
]}

Strigari, Lidia ^{[4
]}

Gentile, Giovanna ^{[5
]}

Cerbelli, Bruna ^{[6
]}

Pellegrini, Patrizia ^{[2
]}

Sgroi, Valentina ^{[1
,2
]}

Occhipinti, Mario ^{[1
,2
]}

Di Pietro, Francesca Romana ^{[1
,2
]}

Rossi, Alessandro ^{[7
]}

Simmaco, Maurizio ^{[8
]}

Mazzuca, Federica ^{[1
,2
]}

Marchetti, Paolo ^{[1
,2
,5
]}

机构：

[1] Sapienza Univ Rome, Dept Clin & Mol Med, Rome, Italy

[2] St Andrea Hosp, Dept Med Oncol, Via Grottarossa 1035, I-00189 Rome, Italy

[3] Santo Spirito Hosp, Rome, Italy

[4] Regina Elena Inst Canc Res, Lab Med Phys & Expert Syst, Rome, Italy

[5] Immacolata IDI IRCSS, Dermopat Inst, Rome, Italy

[6] Sapienza Univ Rome, Dept Radiol Oncol & Pathol Sci, Rome, Italy

[7] Sapienza Univ Rome, Fac Med & Psychol, Rome, Italy

[8] Sapienza Univ Rome, Dept Neurosci Mental Hlth & Sensory Organs NESMOS, Rome, Italy

来源：

ANTICANCER RESEARCH | 2017年 / 37卷 / 05期

关键词：

Breast cancer; taxanes; polymorphisms; ABCB1; P-gp; cytochrome P450; GENETIC POLYMORPHISMS; PERIPHERAL NEUROPATHY; RANDOMIZED-TRIAL; OVARIAN-CANCER; HUMAN LIVER; PACLITAXEL; ABCB1; DOCETAXEL; EXPRESSION; CHEMOTHERAPY;

D O I：

10.21873/anticanres.11610

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Taxanes are widely used to treat breast cancer patients. Taxanes are metabolized in human liver by the cytochrome CYP3A and are substrate of ATP-binding cassette multidrug transporters ABCB1. Single-nucleotide polymorphisms (SNPs) in genes involved in taxanes' metabolism could affect the inter-individual variability in reported toxicities. Materials and Methods: In this retrospective study, 152 women, affected by breast cancer and receiving a taxane-based chemotherapy, were enrolled. A peripheral blood sample was taken for genotyping the following polymorphisms: CYP3A4* 1B (A>G), CYP3A5 * 3 (G>A) and ABCB1 (C1236T; C3435T). Results: We observed an association between ABCB1 3435 T/T and lower grade of toxicities (p=0.05). No other association were found for CYP 3A4 * 1B, 3A5*3 and ABCB1 C1236T. Conclusion: ABCB1 3435 T/T seems to be associated to lower rate of toxicity in patients receiving taxanes. Further prospective and larger studies should be performed to clarify the role of this polymorphism.

引用

页码：2633 / 2639

页数：7

共 50 条

[41] Rechallenging taxanes in recurrent breast cancer in patients treated with (neo-)adjuvant taxane-based therapy
Guo, X.
Loibl, S.
Untch, M.
Moebus, V.
Schwedler, K.
Fasching, P. A.
Barinoff, J.
Holms, F.
Thomssen, C.
Zahm, D. M.
Kreienberg, R.
Hauschild, M.
Eidtmann, H.
Tauchert, S.
Mehta, K.
Von Minckwitz, G.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[42] Early Increases in Multiple Biomarkers Predict Subsequent Cardiotoxicity in Patients With Breast Cancer Treated With Doxorubicin, Taxanes, and Trastuzumab
Thompson, K. A.
BREAST DISEASES, 2015, 26 (03): : 257 - 259
[43] Population Pharmacometric Analyses of Eribulin in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
Majid, Oneeb
Gupta, Anubha
Reyderman, Larisa
Olivo, Martin
Hussein, Ziad
JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (10): : 1134 - 1143
[44] Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes
Chen, Lan
Yan, Xi
Luo, Ting
Tian, Tinglun
He, Ping
Zhong, Xiaorong
CANCER MEDICINE, 2024, 13 (10):
[45] Body mass index as a prognostic factor in operable breast cancer patients treated with adjuvant anthracyclines with or without taxanes
El-Sadda, W.
El-Ibrashi, M.
Abdel-Halim, I.
ANNALS OF ONCOLOGY, 2016, 27
[46] Phase I trial of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.
Possinger, K
Schippinger, W
Kiewe, P
Lange, W
Preiss, J
Niederle, N
Brossart, P
Papke, J
Freier, W
de Velde, HV
Schmid, P
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 66S - 66S
[47] Early Increases in Multiple Biomarkers Predict Subsequent Cardiotoxicity in Patients With Breast Cancer Treated With Doxorubicin, Taxanes, and Trastuzumab
Ky, Bonnie
Putt, Mary
Sawaya, Heloisa
French, Benjamin
Januzzi, James L., Jr.
Sebag, Igal A.
Plana, Juan Carlos
Cohen, Victor
Banchs, Jose
Carver, Joseph R.
Wiegers, Susan E.
Martin, Randolph P.
Picard, Michael H.
Gerszten, Robert E.
Halpern, Elkan F.
Passeri, Jonathan
Kuter, Irene
Scherrer-Crosbie, Marielle
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (08) : 809 - 816
[48] A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes
M. Campone
N. Isambert
E. Bourbouloux
H. Roché
J. Bonneterre
G. Milano
P. Fumoleau
Cancer Chemotherapy and Pharmacology, 2012, 69 : 871 - 879
[49] Pharmacogenetic studies in rectal cancer patients treated with preoperative chemoradiotherapy
Paez Lopez-Bravo, D.
Altes, A.
Sancho-Poch, F. J.
Garriga, J.
Petriz, M.
Pare, L.
del Rio, E.
Barnadas Molins, A.
Baiget, M.
Marcuello, E.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[50] Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide
J Bray
J Sludden
M J Griffin
M Cole
M Verrill
D Jamieson
A V Boddy
British Journal of Cancer, 2010, 102 : 1003 - 1009

← 1 2 3 4 5 →